Moderna Stock Rebounds 4.81% as Cancer Vaccine Focus Builds Ahead of Nasdaq-100 Return

Author: Julian Parker

Date: October 7, 2026

Key Takeaways

• Moderna shares closed at $196.48 on October 7, up 4.81%, as healthcare stocks outperformed a weaker broader market.
• An expanded collaboration with Tempus supports preparations for potential commercialization of Moderna and Merck’s individualized cancer therapy.
• Moderna will rejoin the Nasdaq-100 on October 9, while cautious analyst ratings highlight concerns about its valuation.

Moderna Stock Recovery

On October 7, Moderna's stock rose by 4.81%, closing at $196.48. This increase occurred as healthcare stocks showed resilience in a declining US equity market, bringing attention back to Moderna's cancer-treatment pipeline and its upcoming inclusion in the Nasdaq-100.

This rebound followed a significant decline in the previous session and was bolstered by a new commercial-preparation agreement with Tempus and Merck, although no launch date or treatment approval was confirmed.

Tempus Agreement Advances Commercial Preparations

On the same day, Tempus announced an expanded, multi-year collaboration with Moderna and Merck, aimed at supporting the commercialization of intismeran autogene (V940 or mRNA-4157). Tempus will manage the collection and transfer of tumor tissue and blood samples necessary for next-generation sequencing, which is crucial for the therapy's design and manufacturing process. Financial terms of the agreement were not disclosed.

This collaboration is significant as it lays the groundwork for individualized treatments, which require a coordinated approach to connect patient samples with sequencing data and production capabilities. However, the announcement does not guarantee regulatory approval or revenue generation.

Cancer Vaccine Program Central to Investor Interest

Intismeran autogene is an investigational mRNA-based individualized neoantigen therapy developed by Moderna and Merck, designed to help the immune system recognize cancer cells based on tumor mutations. Positive Phase 3 trial results were announced on August 19, showing the therapy's effectiveness in patients with stage IIB-IV melanoma. While these results strengthen the case for development, they do not resolve all clinical or regulatory questions.

The potential for an oncology business to contribute to Moderna's growth is significant, but actual earnings will depend on regulatory decisions, manufacturing execution, and treatment adoption.

Nasdaq-100 Return as a Trading Catalyst

Moderna is set to join the Nasdaq-100 on October 9, replacing Warner Bros. Discovery. This inclusion is expected to create demand from funds that track the index, potentially increasing the company's visibility among investors. However, the impact of this change on stock price is uncertain, as it does not directly affect the probability of regulatory approval or revenue potential for its cancer treatment program.

Analyst Ratings and Valuation Concerns

Analysts have mixed views on Moderna's stock. Morgan Stanley maintained an Equal-Weight rating while raising its price target to $95, still below the current market price. Citi downgraded the stock to Sell with a target of $80, reflecting concerns that expectations for Moderna's pipeline have not translated into positive stock recommendations. Rothschild Redburn also downgraded the stock to Sell, raising its target to $81, indicating a belief that the market price has risen too high relative to its valuation.

These differing opinions highlight the tension between recognizing the potential of Moderna's treatments and the current market valuation.

Healthcare Sector Context

Moderna's stock gains occurred during a session where healthcare stocks generally performed better than the broader market, with companies like Eli Lilly, Amgen, Johnson & Johnson, and CVS Health also seeing advances. This sector strength provides context for Moderna's rebound, although it remains unclear which factors contributed most significantly to the stock's performance.

The upcoming weeks will be critical in determining whether Moderna can sustain its stock price through continued clinical and commercial progress, as cautious analyst ratings underscore the uncertainty surrounding its future success.